Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multicenter Phase 1/2 Study of ELI-002 in the Adjuvant Setting for Patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have Undergone Neoadjuvant Chemotherapy Followed by Pancreatectomy

Next Previous
Search
Trial Profile

A Prospective, Multicenter Phase 1/2 Study of ELI-002 in the Adjuvant Setting for Patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have Undergone Neoadjuvant Chemotherapy Followed by Pancreatectomy

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 18 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ELI 002 (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Elicio Therapeutics

    • Most Recent Events

    • 23 Feb 2021 According to an Elico Therapeutics media release, the company has received an Investigational New Drug (IND) clearance from the USA Food and Drug Administration for ELI-002. This study is expects to be initiated in the first quarter 2021.
    • 19 Feb 2020 According to an Elico Therapeutics media release, data from this study will be presented RAS-Targeted Drug Discovery Summit in Vienna, Austria, from February 25 to 27, 2020
    • 11 Feb 2020 According to an Elicio Therapeutics media release, Nateras tumor-informed and personalized ctDNA platform, Signatera will be used to select eligible patients whose tumors harbor a mutant KRAS allele and are at high risk for relapse because they have detectable molecular residual disease (MRD) post-surgery. Signatera will also be used to perform serial monitoring to assess the percentage of patients achieving MRD clearance throughout the study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top